Skip to main content
. 2020 Mar 28;46(5):854–887. doi: 10.1007/s00134-020-06022-5
Recommendation

17. If norepinephrine is not available, we suggest using either vasopressin or epinephrine as the first-line vasoactive agent, over other vasoactive agents, for adults with COVID-19 and shock.

Weak recommendation, low-quality evidence.